PRINCETON, N.J., May 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson has been appointed Chief Executive Officer. Mr. Jackson joined Celator in October 2007 as Head of Commercial Development.
"We are delighted to have Scott as the new CEO. He brings more than 20 years of pharmaceutical experience, including 10 years of specialty pharmaceutical experience primarily in oncology," said Dr. Joseph Mollica, Chairman of Celator's Board of Directors. "His senior management experience and commercial and clinical development knowledge will be extremely valuable to the organization as the company moves forward."
Mr. Jackson has extensive experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing, and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor (Johnson & Johnson), Eximias Pharmaceuticals and YM BioSciences. Mr. Jackson holds a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Mr. Jackson succeeds Dr. Andrew Janoff.
"I'm very excited about the future for Celator Pharmaceuticals," said Mr. Jackson. "We have an entrepreneurial spirit and commitment at the company and I look forward to contributing to the company's growth and success."
"Celator has two promising products in clinical development based on
the company's proprietary drug ratio technology platform, CombiPlex (TM).
Results from a Phase 2 study of CPX-1 (a liposomal formulation of
irinotecan:floxuridine) in patients with advanced colorectal cancer will be
reported later this year at major medical conferences. Results from a Phase
1 study with CPX-351 (a liposomal formulation of cytarabine:daunorubicin)
in patients with advanced leukemias will be submitted to a conference
before the end of the year," said Mr. Jackson. "In addition, Celator's
CombiPlex (TM) technology pl
|SOURCE Celator Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved